Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) Short Interest Up 2,558.8% in July

Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) was the target of a significant growth in short interest during the month of July. As of July 31st, there was short interest totaling 45,200 shares, agrowthof2,558.8% from the July 15th total of 1,700 shares. Based on an average daily trading volume, of 452,900 shares, the days-to-cover ratio is presently 0.1 days. Currently,0.0% of the shares of the stock are sold short. Currently,0.0% of the shares of the stock are sold short. Based on an average daily trading volume, of 452,900 shares, the days-to-cover ratio is presently 0.1 days.

Provectus Biopharmaceuticals Trading Up 0.5%

Shares of PVCT stock opened at $0.09 on Friday. The stock has a 50-day moving average price of $0.08 and a 200 day moving average price of $0.09. Provectus Biopharmaceuticals has a 12 month low of $0.07 and a 12 month high of $0.15.

Provectus Biopharmaceuticals Company Profile

Provectus Biopharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes in the United States. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis.